We were delighted to catch up with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) to discuss the interim results for the ECZTEND study (NCT03587805) investigating tralokinumab in patients with atopic dermatitis.
His abstract entitled ‘Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis‘ was presented at AAD VMX, 23-25 April 2021.
- Could you tell us a little about the aims, design and patient population of the ECZTEND study? (0:16)
- What have we learned from the interim efficacy findings of the ECZTEND study? (2:21)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Brian Kim, EADV 2021: Difelikefalin for Pruritus in Atopic Dermatitis
It was a pleasure to meet up with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) to talk about the use of difelikefalin in treating pruritus associated with atopic dermatitis (AD). His presentation entitled ‘Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis’ was given at the EADV 30th Congress, 29 Sep – […]
Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis. His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in […]
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!